Protein tyrosine phosphatase 1B (PTP1B) has been recognized as a major negative regulator of insulin signaling and therefore has been identified as a possible drug target for the treatment of type 2 diabetes and obesity. This evidence concerns the gene PTPN1 and obesity due to melanocortin 4 receptor deficiency.